Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice

Pharmacological Research

Volumn 48, Issue 1, 2003, Pages 49-53

  Gould, Todd D ^a   Gray, Neil A ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Adenomatous polyposis coli; Cancer; Glycogen synthase kinase 3; Lithium; Wnt signaling pathway

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; LITHIUM; PHOSPHOTRANSFERASE INHIBITOR; WNT PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIPOLAR DEPRESSION; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER SIZE; COLON CARCINOGENESIS; COLON POLYPOSIS; CONTROLLED STUDY; DIABETES MELLITUS; EXPERIMENTAL MODEL; GENETIC SUSCEPTIBILITY; LONG TERM CARE; MALE; METASTASIS INHIBITION; MOUSE; MOUSE MUTANT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0038289005     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00096-3     Document Type: Article

References (71)

1. Woodgett J.R. Judging a protein by more than its name: gsk-3. Sci. STKE. 2001:2001;RE12.
2. Cadigan K.M., Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 11:1997;3286-3305.
3. Wodarz A., Nusse R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell. Dev. Biol. 14:1998;59-88.
4. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359:2001;1-16.
5. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 65:2001;391-426.
6. Hedgepeth C.M., Conrad L.J., Zhang J., Huang H.C., Lee V.M., Klein P.S. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev. Biol. 185:1997;82-91.
7. Phiel C.J., Klein P.S. Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 41:2001;789-813.
8. Stambolic V., Ruel L., Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 6:1996;1664-1668.
9. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U.S.A. 93:1996;8455-8459.
10. Gould T.D., Chen G., Manji H.K. Mood stabilizer psychopharmacology. Clin. Neurosci. Res. 2:2002;193-212.
11. Gould T.D., Manji H.K. The wnt signaling pathway in bipolar disorder. Neuroscientist. 8:2002;497-511.
12. Cohen P., Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell. Biol. 2:2001;769-776.
13. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 8:2002;126-132.
14. Maccioni R.B., Munoz J.P., Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res. 32:2001;367-381.
15. Martinez A., Alonso M., Castro A., Perez C., Moreno F.J. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 45:2002;1292-1299.
16. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J.et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7:2000;793-803.
17. Martinez A., Castro A., Dorronsoro I., Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 22:2002;373-384.
18. Tong H., Imahashi K., Steenbergen C., Murphy E. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ. Res. 90:2002;377-379.
19. Chuang D.M., Chen R., Chalecka-Franaszek E., Ren M., Hashimoto R., Senatorov V.et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disorders. 4:2002;116-129.
20. Nonaka S., Chuang D.M. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport. 9:1998;2081-2084.
21. Wei H., Qin Z.H., Senatorov V.V., Wei W., Wang Y., Qian Y.et al. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience. 106:2001;603-612.
22. Cross D.A., Culbert A.A., Chalmers K.A., Facci L., Skaper S.D., Reith A.D. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. 77:2001;94-102.
23. Smith D.G., Buffet M., Fenwick A.E., Haigh D., Ife R.J., Saunders M.et al. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 11:2001;635-639.
24. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87:1996;159-170.
25. Bienz M., Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 103:2000;311-320.
26. Miyoshi Y., Nagase H., Ando H., Horii A., Ichii S., Nakatsuru S.et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum. Mol. Genet. 1:1992;229-233.
27. Fodde R., Smits R., Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer. 1:2001;55-67.
28. Kinzler K.W., Nilbert M.C., Su L.K., Vogelstein B., Bryan T.M., Levy D.B.et al. Identification of FAP locus genes from chromosome 5q21. Science. 253:1991;661-665.
29. Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertsen H.et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 66:1991;589-600.
30. de Silva D.C., Fernando R. Familial adenomatous polyposis. Ceylon Med. J. 43:1998;99-105.
31. Moser A.R., Pitot H.C., Dove W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 247:1990;322-324.
32. Fodde R., Edelmann W., Yang K., van Leeuwen C., Carlson C., Renault B.et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc. Natl. Acad. Sci. U.S.A. 91:1994;8969-8973.
33. Fodde R., Smits R. Disease model: familial adenomatous polyposis. Trends Mol. Med. 7:2001;369-373.
34. Chen G., Rajkowska G., Du F., Seraji-Bozorgzad N., Manji H.K. Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 75:2000;1729-1734.
35. Vestergaard P., Schou M. Lithium treatment in Aarhus. 1. Prevalence. Pharmacopsychiatry. 22:1989;99-100.
36. Cohen Y., Chetrit A., Sirota P., Modan B. Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med. Oncol. 15:1998;32-36.
37. Ahrens B., Muller-Oerlinghausen B., Schou M., Wolf T., Alda M., Grof E.et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J. Affect. Disord. 33:1995;67-75.
38. Ahrens B., Grof P., Moller H.J., Muller-Oerlinghausen B., Wolf T. Extended survival of patients on long-term lithium treatment. Can. J. Psychiatry. 40:1995;241-246.
39. Song J., Medline A., Mason J.B., Gallinger S., Kim Y.I. Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res. 60:2000;5434-5440.
40. Mutanen M., Pajari A.M., Oikarinen S.I. Beef induces and rye bran prevents the formation of intestinal polyps in Apc(Min) mice: relation to beta-catenin and PKC isozymes. Carcinogenesis. 21:2000;1167-1173.
41. Davis C.D., Newman S. Inadequate dietary copper increases tumorigenesis in the Min mouse. Cancer Lett. 159:2000;57-62.
42. Yu C.F., Whiteley L., Carryl O., Basson M.D. Differential dietary effects on colonic and small bowel neoplasia in C57BL/6J Apc Min/+ mice. Dig. Dis. Sci. 46:2001;1367-1380.
43. Huerta S., Irwin R.W., Heber D., Go V.L., Koeffler H.P., Uskokovic M.R.et al. 1alpha25-(OH)(2)-D(3) and its synthetic analogue decrease tumor load in the Apc(min) Mouse. Cancer Res. 62:2002;741-746.
44. Klevay L.M. Lack of a recommended dietary allowance for copper may be hazardous to your health. J. Am. Coll. Nutr. 17:1998;322-326.
45. Sheehan T.J. The medical literature. Let the reader beware. Arch. Int. Med. 140:1980;472-474.
46. Lyman G.H., Williams C.C., Dinwoodie W.R., Preston D. The effect of lithium carbonate administration in patients with advanced small cell bronchogenic carcinoma receiving combination chemotherapy and radiotherapy. Adv. Exp. Med. Biol. 127:1980;207-229.
47. Lyman G.H., Williams C.C., Preston D., Goldman A., Dinwoodie W.R., Saba H.et al. Lithium carbonate in patients with small cell lung cancer receiving combination chemotherapy. Am. J. Med. 70:1981;1222-1229.
48. Lyman G.H., Williams C.C., Preston D. The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy. N. Engl. J. Med. 302:1980;257-260.
49. Greco F.A., Brereton H.D. Effect of lithium carbonate on the neutropenia caused by chemotherapy: a preliminary clinical trial. Oncology. 34:1977;153-155.
50. Stein R.S., Beaman C., Ali M.Y., Hansen R., Jenkins D.D., Jume'an H.G. Lithium carbonate attenuation of chemotherapy-induced neutropenia. N. Engl. J. Med. 297:1977;430-431.
51. El-Domeiri A.A., Messiha F.S., Hsia W.C. Effect of alkali metal salts on Sarcoma I in A/J mice. J. Surg. Oncol. 18:1981;423-429.
52. Ballin A., Aladjem M., Banyash M., Boichis H., Barzilay Z., Gal R.et al. The effect of lithium chloride on tumour appearance and survival of melanoma-bearing mice. Br. J. Cancer. 48:1983;83-87.
53. Jamison K.R. Suicide and bipolar disorder. J. Clin. Psychiatry. 61(Suppl 9):2000;47-51.
54. Baldessarini R.J. Treatment research in bipolar disorder: issues and recommendations. CNS Drugs. 16:2002;721-729.
55. Muller-Oerlinghausen B., Ahrens B., Grof E., Grof P., Lenz G., Schou M.et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr. Scand. 86:1992;218-222.
56. Muller-Oerlinghausen B., Wolf T., Ahrens B., Glaenz T., Schou M., Grof E.et al. Mortality of patients who dropped out from regular lithium prophylaxis: a collaborative study by the International Group for the Study of Lithium-Treated Patients (IGSLI). Acta Psychiatr. Scand. 94:1996;344-347.
57. Chen G., Huang L.D., Jiang Y.M., Manji H.K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72:1999;1327-1330.
58. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276:2001;36734-36741.
59. Gurvich N., Klein P.S. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 96:2002;45-66.
60. Munoz-Montano J.R., Moreno F.J., Avila J., Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411:1997;183-188.
61. Shaldubina A., Agam G., Belmaker R.H. The mechanism of lithium action: state of the art, ten years later. Prog. Neuropsychopharmacol. Biol. Psychiatry. 25:2001;855-866.
62. Gould T.D., Du J., Yuan P., Chen G., Manji H.K. Evidence suggesting activation of the Wnt signaling pathway in rat brain after lithium and valproic acid administration. Biol. Psychiatry. 51:2002;117S.
63. Bhat R.V., Shanley J., Correll M.P., Fieles W.E., Keith R.A., Scott C.W.et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 97:2000;11074-11079.
64. De Sarno P., Li X., Jope R.S. Regulation of Akt and glycogen synthase kinase-3beta phosphorylation by sodium valproate and lithium. Neuropharmacology. 43:2002;1158-1164.
65. Chalecka-Franaszek E., Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. U.S.A. 96:1999;8745-8750.
66. Ding V.W., Chen R.H., McCormick F. Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J. Biol. Chem. 275:2000;32475-32481.
67. Ali A., Hoeflich K.P., Woodgett J.R. Glycogen synthase kinase-3: properties, functions, and regulation. Chem. Rev. 101:2001;2527-2540.
68. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H.et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72:1999;879-882.
69. Chen R.W., Chuang D.M. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J. Biol. Chem. 274:1999;6039-6042.
70. Lu R., Song L., Jope R.S. Lithium attenuates p53 levels in human neuroblastoma SH-SY5Y cells. Neuroreport. 10:1999;1123-1125.
71. Yuan P.X., Huang L.D., Jiang Y.M., Gutkind J.S., Manji H.K., Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 276:2001;31674-31683.